Women Who Test Negative for HPV Can Safely Screen Every Five Years, Study Shows
A new study supports the extension of cervical cancer screening intervals to five years for those with a negative screen result.
A new study supports the extension of cervical cancer screening intervals to five years for those with a negative screen result.
A recent trend analysis indicates that cervical cancer and mortality rates have remained stable or are dropping, in part, because of screening
The Hologic Genius Digital Diagnostics System is expected to derive even more actionable insights from cytology slides for cytotechnologists and pathologists with Google Cloud.
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreThe test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus DNA in cervical samples.
Read MoreThe Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read MoreBluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoreCINtec Plus cytology is the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the Cobas 4800 HPV test.
Read MoreThe new human papillomavirus assay is a real-time polymerase chain reaction-based test that detects 15 recognized high-risk genotypes of HPV DNA.
Read MoreSome argue that cytology adds little to cervical screening efforts, prompting additional discussion on the contribution of cytology to screening protocols.
Read MoreWomen who participated in the screening program were less likely to develop adenosquamous and other rare types of cervical cancer.
Read MoreWuhan University has joined with the Landing Med enterprise to create an international platform for Cloud-based cervical cancer screening.
Read MoreWHO prequalification recognizes the important role that the CareHPV test can have in screening women in emerging countries for HPV.
Read MoreThe Roche test is approved for first-line screening with both SurePath preservative fluid and ThinPrep PreservCyt, the two most common collection media for Pap tests.
Read MoreWomen aged 21 to 65 benefit from screening, and the USPSTF recommends three strategies for screening women aged 30 to 65.
Read MoreGuidelines on diagnostic testing issued by the United States Preventive Services Task Force...
Read MoreFast Track Diagnostics has expanded its comprehensive sexually transmitted infections portfolio by adding an array of human papillomavirus (HPV) tests.
Read MoreA recent study has found large disparities in survival by sex, race, and age, among patients diagnosed with cancers caused by the human papillomavirus.
Read More